Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer

被引:16
|
作者
Habermann, H
Ray, V
Habermann, W
Prins, GS
机构
[1] Univ Illinois, Dept Urol, Chicago, IL 60612 USA
[2] Provident Hosp, Dept Pathol, Chicago, IL USA
[3] Graz Univ, Dept Urol, Graz, Austria
[4] Graz Univ, Dept Otorhinolaryngol Head & Neck Surg, Graz, Austria
来源
JOURNAL OF UROLOGY | 2001年 / 166卷 / 06期
关键词
prostate; prostatic neoplasms; prostatic hyperplasia; GTPase-activating proteins; connexins;
D O I
10.1016/S0022-5347(05)65548-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Gap junctions composed of connexin proteins have an essential role in intercellular communication and differentiation. Dysregulation of connexin expression is believed to have a role in carcinogenesis. The human prostate has been reported to express connexin 32 and 43. However, the expression pattern in prostate cancer is controversial, while to our knowledge connexin expression has not been reported in benign prostatic hyperplasia (BPH). To understand the potential involvement in prostate disease connexin 32 and 43 expression was evaluated in a series of normal prostate, BPH and prostate cancer specimens that were surgically removed due to bladder outlet obstruction. Materials and Methods: Frozen sections of 23 normal, 43 BPH and 40 cancer involved prostates were evaluated for the presence, staining intensity and pattern of connexin 32 and 43 by immunocytochemical testing. Results: In all specimens examined connexin 43 stain was punctate along the borders of the basal epithelial cells, whereas connexin 32 immunolocalized to luminal epithelial cells: In normal prostate connexin 43 and 32 were present in 87% and 65% of specimens, respectively, at low to moderate stain intensity. Importantly none of the normal samples were negative for each connexin. In BPH specimens there was a marked increase in the incidence and intensity of connexin 43 and 32 immunostaining within epithelial cells. In addition, 23% of BPH samples showed strong connexin 43 expression in stromal cells. In contrast, connexin was decreased in prostate cancer specimens, of which 65% and 38% were negative for connexin 43 and 32, respectively, and 28% were negative for each type. In poorly differentiated tumors connexin 43 and 32 were present in only 10% and 40% of tumors, respectively, at low immunostaining intensity. Conclusions: In normal human prostate basal cells communicate via connexin 43 gap junctions, whereas luminal cells communicate via connexin 32 gap junctions. In BPH gap junctional intercellular communication is increased in epithelial and stromal cells, which may have a role in BPH pathogenesis. In prostate cancer gap junctional intercellular communication is decreased, is as indicated by decreased expression of connexin 43 and 32 with severe loss in poorly differentiated prostate cancer. These alterations in connexin expression may have a role in dedifferentiation and tumor progression.
引用
收藏
页码:2267 / 2272
页数:6
相关论文
共 50 条
  • [21] Benign prostatic hyperplasia. Prostate cancer
    Masson-Lecomte, A.
    PROGRES EN UROLOGIE, 2012, 22 (02): : F63 - F68
  • [22] THE ASSOCIATION OF BENIGN PROSTATIC HYPERPLASIA AND CANCER OF THE PROSTATE
    BOSTWICK, DG
    COONER, WH
    DENIS, L
    JONES, GW
    SCARDINO, PT
    MURPHY, GP
    CANCER, 1992, 70 (01) : 291 - 301
  • [23] The level of gene expression of polyamine metabolism proteins in human prostate cancer and benign prostatic hyperplasia
    Bentrad, V. V.
    Zaletok, S. P.
    Stakhovsky, E. O.
    Vitruk, Y. V.
    ANNALS OF ONCOLOGY, 2024, 35 : S1351 - S1351
  • [24] Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia
    Bodker, A
    Bruun, J
    Balslev, E
    Iversen, HG
    Meyhoff, HH
    Andersson, KE
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1999, 33 (04): : 237 - 242
  • [25] NUCLEAR MATRIX PROTEIN-PATTERNS IN HUMAN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE-CANCER
    PARTIN, AW
    GETZENBERG, RH
    CARMICHAEL, MJ
    VINDIVICH, D
    YOO, J
    EPSTEIN, JI
    COFFEY, DS
    CANCER RESEARCH, 1993, 53 (04) : 744 - 746
  • [26] ALTERATIONS IN SPHINGOMYELIN AND FATTY-ACIDS IN HUMAN BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC-CANCER
    NARAYAN, P
    DAHIYA, R
    BIOMEDICA BIOCHIMICA ACTA, 1991, 50 (09) : 1099 - 1108
  • [27] Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia
    Asadi, F
    Farraj, M
    Sharifi, R
    Malakouti, S
    Antar, S
    Kukreja, S
    HUMAN PATHOLOGY, 1996, 27 (12) : 1319 - 1323
  • [28] Prostate inflammation Association with benign prostatic hyperplasia and prostate cancer
    Abdel-Meguid, Taha A.
    Mosli, Hisham A.
    Al-Maghrabi, Jaudah A.
    SAUDI MEDICAL JOURNAL, 2009, 30 (12) : 1563 - 1567
  • [29] Cadmium Concentration and Metallothionein Expression in Prostate Cancer and Benign Prostatic Hyperplasia of Humans
    Lee, Jane-Dar
    Wu, Su-Mei
    Lu, Lieng-Yi
    Yang, Ya-Tang
    Jeng, Shaw-Yeu
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (07) : 554 - 559
  • [30] Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer
    Hillebrand, Ana Caroline
    Pizzolato, Lolita Schneider
    Neto, Brasil Silva
    Branchini, Gisele
    Brum, Ilma Simoni
    PLOS ONE, 2018, 13 (07):